Evidence map›Paper›PMID 30448396›Full record

ArticleTrends in molecular medicine2018

Lipid Mediators, M2 Macrophages, and Pathological Neovascularization.

Steven L Swendeman, Timothy Hla

Abstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Trends in molecular medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Steven L SwendemanVascular Biology Program, Boston Children's Hospital and Department of Surgery, Harvard Medical School, Boston, MA 02115, USA.
Timothy HlaVascular Biology Program, Boston Children's Hospital and Department of Surgery, Harvard Medical School, Boston, MA 02115, USA. Electronic address: timothy.hla@childrens.harvard.edu.
Boston Children's Hospital · USHarvard University · US

Funding

Mechanisms of sphingolipid signaling in vascular health and diseaseR35HL135821 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI HLA, TIMOTHY TUN · 2017 to 2023
$6.3M
NHLBI NIH HHS R35 HL135821
6 · The paper itself

Abstract

Sasaki and colleagues [1] (JCI Insight 2018;3,e96902) identified the leukocyte inflammatory lipid mediator leukotriene B4 (LTB4)/LTB4 receptor 1 receptor-signaling axis in M2 macrophages as a causal pathway for the vascular endothelial growth factor-dependent pathological neovascularization in a mouse model that mimics wet age-related macular degeneration. This observation provides a novel mechanism by which an eicosanoid lipid mediator drives retinal vascular pathology and suggests a novel therapeutic target for proliferative retinal vascular diseases.

Indexed as

Leukotriene B4Vascular Endothelial Growth Factor AAnimalsEicosanoidsHumansMacrophagesMiceNeovascularization, PathologicEicosanoidsLeukotriene B4Vascular Endothelial Growth Factor Aage-related macular degenerationeicosanoidsleukotrienesM2-polarized macrophagespathological neovascularization

Identifiers

PMID30448396
PMCPMC6876743
OpenAlexW2901699322

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.